Bosh sahifaATHA • NASDAQ
add
Athira Pharma Inc
Yopilish kursi
4,58 $
Kunlik diapazon
4,33 $ - 4,74 $
Yillik diapazon
2,19 $ - 8,26 $
Bozor kapitalizatsiyasi
17,79 mln USD
Oʻrtacha hajm
31,58 ming
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | sen, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | — | — |
Joriy xarajat | 6,87 mln | -73,04% |
Sof foyda | -6,61 mln | 77,00% |
Sof foyda marjasi | — | — |
Har bir ulushga tushum | — | — |
EBITDA | -6,63 mln | 73,74% |
Amaldagi soliq stavkasi | — | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | sen, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 25,23 mln | -63,36% |
Jami aktivlari | 30,03 mln | -65,18% |
Jami passivlari | 3,25 mln | -88,67% |
Umumiy kapital | 26,79 mln | — |
Tarqatilgan aksiyalar | 3,94 mln | — |
Narxi/balansdagi bahosi | 0,67 | — |
Aktivlardan daromad | -52,41% | — |
Kapitaldan daromad | -56,62% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | sen, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -6,61 mln | 77,00% |
Operatsiyalardan naqd pul | -4,67 mln | 79,72% |
Sarmoyadan naqd pul | 5,65 mln | -68,66% |
Moliyadan naqd pul | 0,00 | -100,00% |
Naqd pulning sof oʻzgarishi | 986,00 ming | 119,83% |
Boʻsh pul | -3,66 mln | 63,82% |
Haqida
Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
Tashkil etilgan
2011
Sayt
Xodimlar soni
26
